Circulating fibrocytes as biomarker of prognosis in Hermansky-Pudlak syndrome

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 12, 2014, Pages 1395-1401

  Trimble, Aaron ^a   Gochuico, Bernadette R ^b   Markello, Thomas C ^b,c   Fischer, Roxanne ^b   Gahl, William A ^b,c   Lee, Jae K ^d   Kim, Youngchul ^d   Burdick, Marie D ^a   Strieter, Robert M ^a   Mehrad, Borna ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Medical Genetics Branch   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chemokines; CXCR4 receptors; Interstitial lung diseases; Stem cells

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD ANALYSIS; CELLS; CIRCULATING FIBROCYTE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYPOTHESIS; LONGITUDINAL STUDY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OCULAR ALBINISM; PHENOTYPE; PROGNOSIS; BLOOD; CASE CONTROL STUDY; HERMANSKI-PUDLAK SYNDROME; MESENCHYMAL STROMA CELL; MORTALITY; PHYSIOLOGY; SURVIVAL ANALYSIS;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HERMANSKI-PUDLAK SYNDROME; HUMANS; LONGITUDINAL STUDIES; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PROGNOSIS; RECEPTORS, CXCR4; SURVIVAL ANALYSIS;

EID: 84919360725     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201407-1287OC     Document Type: Article

References (37)

1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165: 277-304.
2. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al.; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188: 733-748.
3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183: 788-824.
4. Keeley EC, Mehrad B, Strieter RM. Fibrocytes: Bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol 2010;42: 535-542.
5. Mehrad B, Strieter RM. Fibrocytes and the pathogenesis of diffuse parenchymal lung disease. Fibrogenesis Tissue Repair 2012;5: S22.
6. Mehrad B, Burdick MD, Strieter RM. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009;41: 1708-1718.
7. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005; 166: 675-684.
8. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004;114: 438-446.
9. Andersson-Sjöland A, de Alba CG, Nihlberg K, Becerril C, Ramírez R, Pardo A, Westergren-Thorsson G, Selman M. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008;40: 2129-2140.
10. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007;353: 104-108.
11. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179: 588-594.
12. Seward SL Jr, Gahl WA. Hermansky-Pudlak syndrome: Health care throughout life. Pediatrics 2013;132: 153-160.
13. Brantly M, Avila NA, Shotelersuk V, Lucero C, Huizing M, Gahl WA. Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. Chest 2000;117: 129-136.
14. Nakatani Y, Nakamura N, Sano J, Inayama Y, Kawano N, Yamanaka S, Miyagi Y, Nagashima Y, Ohbayashi C, Mizushima M, et al. Interstitial pneumonia in Hermansky-Pudlak syndrome: Significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch 2000;437: 304-313.
15. Witkop CJ, Almadovar C, Piñeiro B, Nuñez Babcock M. Hermansky-Pudlak syndrome (HPS). An epidemiologic study. Ophthalmic Paediatr Genet 1990;11: 245-250.
16. Trimble A, Burdick MD, Fischer R, Gahl WA, Gochuico BR, Mehrad B. Elevation in peripheral fibrocyte counts correlates with development of interstitial lung disease in patients with Hermansky-Pudlak syndrome. Presented at the American College of Chest Physicians Meeting. October 26-31, 2013, Chicago, IL.
17. O'Brien K, Troendle J, Gochuico BR, Markello TC, Salas J, Cardona H, Yao J, Bernardini I, Hess R, Gahl WA. Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 2011;103: 128-134.
18. Sakai N, Wada T, Yokoyama H, Lipp M, Ueha S, Matsushima K, Kaneko S. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA 2006;103: 14098-14103.
19. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: Causes and assessment. Am J Med 1990;88: 396-404.
20. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, et al.; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176: 636-643.
21. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007;132: 1652-1658.
22. Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Jang SJ, Colby TV. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007;132: 214-220.
23. Song JS, Kang CM, Kang HH, Yoon HK, Kim YK, Kim KH, Moon HS, Park SH. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med 2010;42: 465-472.
24. Gahl WA, Huizing M. Hermansky-Pudlak syndrome. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews. Seattle: University of Washington [created 2000 Jul 24; revised 2013 Feb 28]. Available from: Http://www.ncbi.nlm.nih.gov/books/NBK1287/
25. Shotelersuk V, Gahl WA. Hermansky-Pudlak syndrome: Models for intracellular vesicle formation. Mol Genet Metab 1998;65: 85-96.
26. Gahl WA, Brantly M, Kaiser-Kupfer MI, Iwata F, Hazelwood S, Shotelersuk V, Duffy LF, Kuehl EM, Troendle J, Bernardini I. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med 1998;338: 1258-1264.
27. Anderson PD, Huizing M, Claassen DA, White J, Gahl WA. Hermansky-Pudlak syndrome type 4 (HPS-4): Clinical and molecular characteristics. Hum Genet 2003;113: 10-17.
28. Gochuico BR, Huizing M, Golas GA, Scher CD, Tsokos M, Denver SD, Frei-Jones MJ, Gahl WA. Interstitial lung disease and pulmonary fibrosis in Hermansky-Pudlak syndrome type 2, an adaptor protein-3 complex disease. Mol Med 2012;18: 56-64.
29. Avila NA, Brantly M, Premkumar A, Huizing M, Dwyer A, Gahl WA. Hermansky-Pudlak syndrome: Radiography and CT of the chest compared with pulmonary function tests and genetic studies. AJR Am J Roentgenol 2002;179: 887-892.
30. Keeley EC, Mehrad B, Janardhanan R, Salerno M, Hunter JR, Burdick MM, Field JJ, Strieter RM, Kramer CM. Elevated circulating fibrocyte levels in patients with hypertensive heart disease. J Hypertens 2012;30: 1856-1861.
31. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 2006;35: 175-181.
32. Reich B, Schmidbauer K, Rodriguez Gomez M, Johannes Hermann F, Göbel N, Brühl H, Ketelsen I, Talke Y, Mack M. Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. Kidney Int 2013;84: 78-89.
33. Peelen L, Wells AU, Prijs M, Blumenthal JP, van Steenwijk RP, Jonkers RE, Peek N, Bresser P. Fibrotic idiopathic interstitial pneumonias: Mortality is linked to a decline in gas transfer. Respirology 2010;15: 1233-1243.
34. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184: 1382-1389.
35. Schmidt SL, Tayob N, Han MK, Zappala C, Kervitsky D, Murray S, Wells AU, Brown KK, Martinez FJ, Flaherty KR. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014;145: 579-585.
36. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156: 684-691.
37. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, et al. Predicting survival across chronic interstitial lung disease: The ILD-GAP model. Chest 2014; 145: 723-728.